Advances in radiotherapy and immunity in hepatocellular carcinoma DOI Creative Commons
Yuhan Yang,

Liting Xiong,

Mengyuan Li

et al.

Journal of Translational Medicine, Journal Year: 2023, Volume and Issue: 21(1)

Published: Aug. 4, 2023

Primary liver cancer is one of the most common malignant tumours worldwide; it caused approximately 830,000 deaths in 2020. Hepatocellular carcinoma (HCC) type primary cancer, accounting for over 80% all cases. Various methods, including surgery, chemotherapy, radiotherapy, and radiofrequency ablation, have been widely used treatment HCC. With advancement technology, radiotherapy has become increasingly important comprehensive However, due to insufficient sensitivity tumour cells radiation, there are still multiple limitation clinical application radiotherapy. In recent years, role immunotherapy revealed, more researchers turned their attention combined hope achieving better outcomes. This article reviews progress on radiation therapy HCC current status its with immunotherapy, discusses prospects value radioimmunotherapy

Language: Английский

Angiogenic signaling pathways and anti-angiogenic therapy for cancer DOI Creative Commons

Zhenling Liu,

Huanhuan Chen, Lili Zheng

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: May 11, 2023

Abstract Angiogenesis, the formation of new blood vessels, is a complex and dynamic process regulated by various pro- anti-angiogenic molecules, which plays crucial role in tumor growth, invasion, metastasis. With advances molecular cellular biology, biomolecules such as growth factors, chemokines, adhesion factors involved angiogenesis has gradually been elucidated. Targeted therapeutic research based on these molecules driven treatment to become promising strategy anti-tumor therapy. The most widely used agents include monoclonal antibodies tyrosine kinase inhibitors (TKIs) targeting vascular endothelial factor (VEGF) pathway. However, clinical benefit this modality still limited due several defects adverse events, acquired drug resistance, recurrence, lack validated biomarkers, impel further mechanisms angiogenesis, development multiple drugs combination therapy figure out how improve efficacy. Here, we broadly summarize signaling pathways discuss current challenges We also propose approaches efficacy provide perspective for

Language: Английский

Citations

558
Liver tumour immune microenvironment subtypes and neutrophil heterogeneity DOI
Ruidong Xue, Qiming Zhang, Qi Cao

et al.

Nature, Journal Year: 2022, Volume and Issue: 612(7938), P. 141 - 147

Published: Nov. 9, 2022

Language: Английский

Citations

492
A global view of the interplay between non-alcoholic fatty liver disease and diabetes DOI
Norbert Stefan, Kenneth Cusi

The Lancet Diabetes & Endocrinology, Journal Year: 2022, Volume and Issue: 10(4), P. 284 - 296

Published: Feb. 17, 2022

Language: Английский

Citations

416
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits DOI Creative Commons
Moritz Peiseler, Robert F. Schwabe, Jochen Hampe

et al.

Journal of Hepatology, Journal Year: 2022, Volume and Issue: 77(4), P. 1136 - 1160

Published: June 22, 2022

Language: Английский

Citations

323
Lipid alterations in chronic liver disease and liver cancer DOI Creative Commons
Bichitra Paul, Monika Lewińska, Jesper B. Andersen

et al.

JHEP Reports, Journal Year: 2022, Volume and Issue: 4(6), P. 100479 - 100479

Published: March 26, 2022

Lipids are a complex and diverse group of molecules with crucial roles in many physiological processes, as well the onset, progression, maintenance cancers. Fatty acids cholesterol building blocks lipids, orchestrating these metabolic processes. In liver, lipid alterations prevalent cause consequence chronic hepatitis B C virus infections, alcoholic hepatitis, non-alcoholic fatty liver disease steatohepatitis. Recent developments lipidomics have also revealed that dynamic changes triacylglycerols, phospholipids, sphingolipids, ceramides, acids, involved development progression primary cancer. Accordingly, transcriptional landscape metabolism suggests carcinogenic role increasing sterol synthesis. However, limited mechanistic insights into nature hepatic lipidome so far hindered effective therapies.

Language: Английский

Citations

210
Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma DOI Creative Commons
Julien Caldéraro, Tobias Paul Seraphin, Tom Luedde

et al.

Journal of Hepatology, Journal Year: 2022, Volume and Issue: 76(6), P. 1348 - 1361

Published: May 16, 2022

Hepatocellular carcinoma (HCC) currently represents the fifth most common malignancy and third-leading cause of cancer-related death worldwide, with incidence mortality rates that are increasing. Recently, artificial intelligence (AI) has emerged as a unique opportunity to improve full spectrum HCC clinical care, by improving risk prediction, diagnosis, prognostication. AI approaches include computational search algorithms, machine learning (ML) deep (DL) models. ML consists computer running repeated iterations models, in order progressively performance specific task, such classifying an outcome. DL models subtype ML, based on neural network structures inspired neuroanatomy human brain. A growing body recent data now apply diverse sources - including electronic health record data, imaging modalities, histopathology molecular biomarkers accuracy detection prediction treatment response. Despite promise these early results, future research is still needed standardise both generalisability interpretability results. If challenges can be overcome, potential profoundly change way which care provided patients or at HCC.

Language: Английский

Citations

198
Advances in the clinical management of uveal melanoma DOI
Richard D. Carvajal, Joseph J. Sacco, Martine J. Jager

et al.

Nature Reviews Clinical Oncology, Journal Year: 2023, Volume and Issue: 20(2), P. 99 - 115

Published: Jan. 4, 2023

Language: Английский

Citations

146
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy DOI Creative Commons
Qian Li, Jingjing Han,

Yonglin Yang

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Dec. 19, 2022

Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide. Sorafenib monotherapy been the standard of first-line treatment for advanced HCC long time, but there are still many shortcomings. In recent years, with deepening research on tumor immune microenvironment, researchers have begun to explore new approaches in immunotherapy, introduction checkpoint inhibitors brought fundamental changes HCC. Programmed cell death protein 1 (PD-1) is an molecule that plays important role down-regulating system function promoting tolerance. ligand (PDL-1) involved evasion by binding PD-1, resulting failure treatment. Currently, immunotherapy targeting PD-1/PD-L1 axis achieved unprecedented success HCC, it also faces great challenges, its low remission be solved. For most patients pathway not only limiting factor antitumor immunity, blocking enough stimulate effective response; thus, combination therapy may better option. this study, microenvironment were reviewed clarify feasibility anti-PD-1/PD-L1 therapy, series clinical trials summarized verify safety efficacy newly developed Furthermore, we focused hyperprogressive disease drug resistance gain understanding blockade as promising

Language: Английский

Citations

123
Fluorescent Probes for Disease Diagnosis DOI Creative Commons
Xin Wang, Qi Ding, Robin R. Groleau

et al.

Chemical Reviews, Journal Year: 2024, Volume and Issue: 124(11), P. 7106 - 7164

Published: May 17, 2024

The identification and detection of disease-related biomarkers is essential for early clinical diagnosis, evaluating disease progression, the development therapeutics. Possessing advantages high sensitivity selectivity, fluorescent probes have become effective tools monitoring active molecules at cellular level in vivo. In this review, we describe current designed quantification key bioactive associated with common diseases, such as organ damage, inflammation, cancers, cardiovascular brain disorders. We emphasize strategies behind design capable biomarker diagnosis cover some aspects combined diagnostic/therapeutic based on regulating molecules. This review concludes a discussion challenges outlook probes, highlighting future avenues research that should enable these to achieve accurate biomedical applications.

Language: Английский

Citations

106
Alternative splicing and related RNA binding proteins in human health and disease DOI Creative Commons

Yining Tao,

Qi Zhang, Haoyu Wang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Feb. 2, 2024

Abstract Alternative splicing (AS) serves as a pivotal mechanism in transcriptional regulation, engendering transcript diversity, and modifications protein structure functionality. Across varying tissues, developmental stages, or under specific conditions, AS gives rise to distinct splice isoforms. This implies that these isoforms possess unique temporal spatial roles, thereby associating with standard biological activities diseases. Among these, AS-related RNA-binding proteins (RBPs) play an instrumental role regulating alternative events. Under physiological the diversity of mediated by influences structure, function, interaction, localization proteins, participating differentiation development array tissues organs. pathological alterations are linked various diseases, particularly cancer. These changes can lead gene patterns, culminating loss For instance, cancer, abnormalities RBPs may result aberrant expression cancer-associated genes, promoting onset progression tumors. also associated numerous neurodegenerative diseases autoimmune Consequently, study across different holds significant value. review provides detailed account recent advancements tissue which aids deepening understanding complexity offers new insights methodologies for precision medicine.

Language: Английский

Citations

88